Portal de Periódicos da CAPES

Tumor Necrosis Factor-α Inhibitor Associated Ulcerative Colitis

2007; Elsevier BV; Volume: 333; Issue: 3 Linguagem: Inglês

10.1097/maj.0b013e3180312362

1538-2990

Kara Prescott, Melissa Costner, Stanley Cohen, Salahuddin Kazi,

Autoimmune and Inflammatory Disorders Research

Background Flares or onset of inflammatory bowel disease in association with immunosuppression has been reported in the literature. Methods We studied 4 cases of patients with rheumatic disease who developed or had a flare of ulcerative colitis either after initiation of or while taking a tumor necrosis factor-α inhibitor. Results We identified 4 patients, three male and one female. Two of the male patients had a seronegative spondyloarthropathy and one had rheumatoid arthritis. The female patient had amyopathic dermatomyositis. Two of the 4 patients had ulcerative colitis prior to tumor necrosis factor-α treatment. Both of these patients had quiescent ulcerative colitis that flared after they began taking etanercept. Two patients developed de novo ulcerative colitis while taking a tumor necrosis factor-α inhibitor. Conclusions The data presented in these 4 cases supports a temporal relationship between initiating a tumor necrosis factor-α inhibitor and onset or flare of ulcerative colitis. These observations raise the possibility that tumor necrosis factor-α inhibitor therapy, which has been used as treatment for inflammatory bowel disease, may rarely be a factor in the development of disease.